NASDAQ:NTLAIntellia Therapeutics Stock Price, Forecast & News

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NTLA stock has increased by 87.2% and is now trading at $23.81. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intellia Therapeutics.

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Intellia Therapeutics.

Intellia Therapeutics Inc (NASDAQ:NTLA) released its earnings results on Thursday, May, 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.24. The business had revenue of $12.92 million for the quarter, compared to analysts' expectations of $21.98 million. Intellia Therapeutics had a negative return on equity of 40.89% and a negative net margin of 239.98%. The business's quarterly revenue was up 23.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.49) EPS. View Intellia Therapeutics' earnings history.

6 brokers have issued 12 month price objectives for Intellia Therapeutics' stock. Their forecasts range from $20.00 to $57.50. On average, they anticipate Intellia Therapeutics' stock price to reach $28.90 in the next year. This suggests a possible upside of 21.4% from the stock's current price. View analysts' price targets for Intellia Therapeutics.

Press coverage about NTLA stock has trended somewhat positive on Sunday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Intellia Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Intellia Therapeutics.

Intellia Therapeutics saw a decline in short interest in June. As of June 30th, there was short interest totaling 10,030,000 shares, a decline of 7.2% from the June 15th total of 10,810,000 shares. Based on an average daily trading volume, of 916,100 shares, the short-interest ratio is currently 10.9 days. Currently, 25.1% of the shares of the company are short sold. View Intellia Therapeutics' Current Options Chain.

Some companies that are related to Intellia Therapeutics include Neogen (NEOG), Meridian Bioscience (VIVO), Heska (HSKA), Myriad Genetics (MYGN), Quotient (QTNT), Lantheus (LNTH), Vermillion (VRML), Oxford Immunotec Global (OXFD), Celldex Therapeutics (CLDX), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), ImmuCell (ICCC), Arca Biopharma (ABIO) and Akers Biosciences (AKER). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Square (SQ), InVitae (NVTA), Advanced Micro Devices (AMD), Cisco Systems (CSCO) and Sangamo Therapeutics (SGMO).

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NTLA stock can currently be purchased for approximately $23.81.

Intellia Therapeutics has a market capitalization of $1.22 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe.

The official website for Intellia Therapeutics is www.intelliatx.com.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]